{"component": "definition", "props": {"groups": [{"samples": [{"hash": "95keJvPQ6jt", "uri": "https://meglc.gov.in/pdf/Draft%20Meghalaya%20Occupational%20Safety,%20Health%20and%20Working%20Condition%20Rules,%202024.pdf", "label": "meglc.gov.in", "score": 17.7691230774, "published": false}, {"hash": "hnTYPfrIi3E", "uri": "https://aioe.in/wp-content/uploads/2022/05/Chandigarh-Occupational-Safety-Rules2021-Draft.pdf", "label": "aioe.in", "score": 16.9461174011, "published": false}, {"hash": "bXwnHcjdWtk", "uri": "https://legalitysimplified.com/wp-content/uploads/2022/01/Occupational-safety-chandigarh.pdf", "label": "legalitysimplified.com", "score": 11.0150585175, "published": false}], "snippet_links": [{"key": "quantity-of", "type": "clause", "offset": [150, 161]}, {"key": "per-cent", "type": "definition", "offset": [234, 242]}, {"key": "dry-weight", "type": "definition", "offset": [251, 261]}, {"key": "in-the-case", "type": "clause", "offset": [298, 309]}, {"key": "similar-products", "type": "definition", "offset": [324, 340]}, {"key": "the-material", "type": "clause", "offset": [423, 435]}, {"key": "other-media", "type": "clause", "offset": [559, 570]}], "snippet": "means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid, a quantity of soluble lead compound exceeding, when calculated as lead monoxide, five per cent of the \u201cdry weight\u201d of the portion taken for analysis. In the case of paints and similar products and other mixtures containing oil or fat the \u201cdry weight\u201d means the dry weight of the material remaining after the substance has been thoroughly mixed and treated with suitable solvents to remove oil, fats, varnish or other media.", "size": 33, "hash": "fe53e7a82818a7bd4670db3932e2b438", "id": 1}, {"samples": [{"hash": "7Xvu1zE0UM7", "uri": "https://www.simpliance.in/files/labour_code_docs/88762344_the-punjab-occupational-safety-health-and-working-conditions-rules-2021.pdf", "label": "www.simpliance.in", "score": 10.691991806, "published": false}, {"hash": "4iu0OIwYQux", "uri": "https://www.jklabour.com/uploads/files/f944570d588c2761bbb3.pdf", "label": "www.jklabour.com", "score": 10.553730011, "published": false}, {"hash": "kszxmgXbJj6", "uri": "https://dcimanipur.gov.in/documents/ManipurFactoriesRules2019_Upload.pdf", "label": "dcimanipur.gov.in", "score": 10.4332647324, "published": false}], "snippet_links": [{"key": "five-percent", "type": "clause", "offset": [225, 237]}, {"key": "dry-weight", "type": "definition", "offset": [245, 255]}], "snippet": "means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.", "size": 29, "hash": "f698bce13c26bfb703f822e780f7fc30", "id": 2}, {"samples": [{"hash": "6wlJ604XC2X", "uri": "/contracts/6wlJ604XC2X#lead-compound", "label": "Exclusive Research Collaboration, License and Commercialization Agreement (Vertex Pharmaceuticals Inc / Ma)", "score": 23.6830940247, "published": true}, {"hash": "kKte11NmiTM", "uri": "/contracts/kKte11NmiTM#lead-compound", "label": "Exclusive Research Collaboration, License and Commercialization Agreement (Vertex Pharmaceuticals Inc / Ma)", "score": 21.0, "published": true}, {"hash": "jLuM6apysp9", "uri": "/contracts/jLuM6apysp9#lead-compound", "label": "Exclusive Research Collaboration, License and Commercialization Agreement (Vertex Pharmaceuticals Inc / Ma)", "score": 21.0, "published": true}], "snippet_links": [{"key": "product-candidate", "type": "definition", "offset": [11, 28]}, {"key": "stage-of-development", "type": "clause", "offset": [59, 79]}, {"key": "on-the-effective-date", "type": "clause", "offset": [115, 136]}, {"key": "at-any-time", "type": "clause", "offset": [150, 161]}, {"key": "in-development", "type": "definition", "offset": [183, 197]}, {"key": "for-development", "type": "clause", "offset": [269, 284]}], "snippet": "means that Product Candidate which is in the most advanced stage of development. VX-680 shall be the Lead Compound on the Effective Date. If there is at any time no Product Candidate in development, then the Lead Compound shall mean the next Product Candidate selected for development.", "size": 10, "hash": "1f6e1e540f2a6addc6725a2eeee08f9b", "id": 3}, {"samples": [{"hash": "2gBppf080X9", "uri": "https://www.ricago.com/assets/front/base/file/file_management/608.pdf", "label": "www.ricago.com", "score": 16.4504261017, "published": false}, {"hash": "8EYgOHr6fMy", "uri": "https://labour.sikkim.gov.in/Uploads/AllFiles/133.pdf", "label": "labour.sikkim.gov.in", "score": 12.1567420959, "published": false}, {"hash": "iHODhZ6Ip3P", "uri": "https://storage.hrylabour.gov.in/uploads/labour_laws/Y2021/Sep/W3/D17/1631879843.pdf", "label": "storage.hrylabour.gov.in", "score": 10.8548936844, "published": false}], "snippet_links": [{"key": "quantity-of", "type": "clause", "offset": [150, 161]}, {"key": "per-cent", "type": "definition", "offset": [234, 242]}, {"key": "dry-weight", "type": "definition", "offset": [250, 260]}, {"key": "method-of-treatment", "type": "clause", "offset": [300, 319]}], "snippet": "means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid, a quantity of soluble lead compound exceeding, when calculated as lead monoxide, five per cent of the dry weight of the portion taken for analysis. The method of treatment shall be as follows:", "size": 8, "hash": "f2cb7494102b1bf8f60dcc656f3c5ffc", "id": 4}, {"samples": [{"hash": "4nfSTuejOS", "uri": "/contracts/4nfSTuejOS#lead-compound", "label": "Collaborative Research and License Agreement (Accelrys, Inc.)", "score": 22.1991786957, "published": true}, {"hash": "6Cmci8nWpw5", "uri": "/contracts/6Cmci8nWpw5#lead-compound", "label": "Collaborative Research and License Agreement (Symyx Technologies Inc)", "score": 18.0, "published": true}, {"hash": "3a1B7sj7ZEN", "uri": "/contracts/3a1B7sj7ZEN#lead-compound", "label": "Collaborative Research and License Agreement (Symyx Technologies Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "library-compound", "type": "definition", "offset": [8, 24]}, {"key": "research-plan", "type": "definition", "offset": [123, 136]}, {"key": "research-committee", "type": "definition", "offset": [147, 165]}, {"key": "procedure-for", "type": "clause", "offset": [203, 216]}, {"key": "exhibit-b", "type": "definition", "offset": [261, 270]}, {"key": "it-is-understood-and-agreed-that", "type": "definition", "offset": [279, 311]}], "snippet": "means a Library Compound which meets the specific physical, chemical and/or catalytic properties established either in the Research Plan or by the Research Committee for identifying a Lead Compound. The procedure for identifying a Lead Compound is set forth on Exhibit B hereto. It is understood and agreed that any Library Compound that is transferred from Symyx to TDCC and subsequently commercialized by or under authority of TDCC or its Affiliates shall be deemed a Lead Compound.", "size": 8, "hash": "7ae826d5cac67277cb9b51e908358334", "id": 5}, {"samples": [{"hash": "jLgejHPlKLW", "uri": "/contracts/jLgejHPlKLW#lead-compound", "label": "Agreement for the Provision of Funding", "score": 33.2227554321, "published": true}, {"hash": "jU5lKhX8RSM", "uri": "/contracts/jU5lKhX8RSM#lead-compound", "label": "Agreement for the Provision of Funding (PTC Therapeutics, Inc.)", "score": 32.3169059753, "published": true}, {"hash": "kgs2Hcpy1Ih", "uri": "/contracts/kgs2Hcpy1Ih#lead-compound", "label": "Agreement for the Provision of Funding (PTC Therapeutics, Inc.)", "score": 22.3702945709, "published": true}], "snippet_links": [{"key": "programme-compound", "type": "definition", "offset": [10, 28]}, {"key": "the-criteria", "type": "clause", "offset": [45, 57]}, {"key": "set-out", "type": "definition", "offset": [58, 65]}, {"key": "milestone-1", "type": "definition", "offset": [69, 80]}, {"key": "schedule-3", "type": "clause", "offset": [84, 94]}, {"key": "in-the-field", "type": "clause", "offset": [103, 115]}], "snippet": "means any Programme Compound which satisfies the criteria set out in Milestone 1 in Schedule 3 for use in the Field;", "size": 6, "hash": "bbbf65294941f46b575ec12fbff138c9", "id": 6}, {"samples": [{"hash": "gtQP8S7shv2", "uri": "/contracts/gtQP8S7shv2#lead-compound", "label": "Service Agreement (Signal Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "YjIfgMjlsD", "uri": "/contracts/YjIfgMjlsD#lead-compound", "label": "Service Agreement (Signal Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "KGtpYU2Uwt", "uri": "/contracts/KGtpYU2Uwt#lead-compound", "label": "Service Agreement (Signal Pharmaceuticals Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "section-32", "type": "definition", "offset": [34, 45]}], "snippet": "will have the meaning assigned in Section 3.2.", "size": 6, "hash": "0101b4d2a7ca4945b8a0f2f19241a6c0", "id": 7}, {"samples": [{"hash": "kuAPiXMERk0", "uri": "/contracts/kuAPiXMERk0#lead-compound", "label": "Collaboration and License Agreement", "score": 31.3408622742, "published": true}, {"hash": "fkc9bftpxIp", "uri": "/contracts/fkc9bftpxIp#lead-compound", "label": "Collaboration and License Agreement (Ligand Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "NLxlZ5c7Pe", "uri": "/contracts/NLxlZ5c7Pe#lead-compound", "label": "Collaboration and License Agreement (Ligand Pharmaceuticals Inc)", "score": 21.0, "published": true}], "snippet_links": [{"key": "schering-compound", "type": "definition", "offset": [17, 34]}, {"key": "with-respect-to", "type": "clause", "offset": [35, 50]}, {"key": "agree-to", "type": "clause", "offset": [69, 77]}, {"key": "development-candidate", "type": "definition", "offset": [134, 155]}], "snippet": "means any Hit or Schering Compound with respect to which the Parties agree to initiate a program of medicinal chemistry to identify a Development Candidate based upon the structure of such Hit or Schering Compound.", "size": 5, "hash": "4bf17a015595804865bd342346776190", "id": 8}, {"samples": [{"hash": "emeRKDrqikU", "uri": "/contracts/emeRKDrqikU#lead-compound", "label": "Focused Collaboration Agreement (Regeneron Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "3uu1Ht3AeOi", "uri": "https://investor.regeneron.com/static-files/52abae9f-6106-45d0-9aa1-6f38568879c3", "label": "investor.regeneron.com", "score": 9.965092659, "published": false}, {"hash": "bNv3NN3IRdM", "uri": "https://investor.regeneron.com/index.php/static-files/52abae9f-6106-45d0-9aa1-6f38568879c3", "label": "investor.regeneron.com", "score": 9.3312797546, "published": false}], "snippet_links": [{"key": "research-compound", "type": "definition", "offset": [8, 25]}, {"key": "success-criteria", "type": "definition", "offset": [61, 77]}, {"key": "ready-to", "type": "clause", "offset": [81, 89]}, {"key": "development-of", "type": "clause", "offset": [125, 139]}, {"key": "clinical-supplies", "type": "definition", "offset": [140, 157]}, {"key": "section-33", "type": "definition", "offset": [170, 181]}, {"key": "during-the-research-term", "type": "clause", "offset": [182, 206]}, {"key": "tail-period", "type": "definition", "offset": [210, 221]}, {"key": "the-terms", "type": "definition", "offset": [223, 232]}, {"key": "development-compound", "type": "clause", "offset": [233, 253]}], "snippet": "means a Research Compound that has been demonstrated to meet Success Criteria as ready to begin regulated safety studies and development of clinical supplies pursuant to Section 3.3 during the Research Term or Tail Period. The terms Development Compound and Lead Compound may be used interchangeably.", "size": 5, "hash": "6ddf64ebecb8bff0af5db8ae393937b2", "id": 9}, {"samples": [{"hash": "lV5k2MHNIGn", "uri": "/contracts/lV5k2MHNIGn#lead-compound", "label": "Collaborative Research and License Agreement (Nitromed Inc)", "score": 21.0, "published": true}, {"hash": "i6GIOhJ5Y6r", "uri": "/contracts/i6GIOhJ5Y6r#lead-compound", "label": "Collaborative Research and License Agreement (Nitromed Inc)", "score": 21.0, "published": true}, {"hash": "e4DV06jqnKT", "uri": "/contracts/e4DV06jqnKT#lead-compound", "label": "Collaborative Research and License Agreement (Archemix Corp.)", "score": 21.0, "published": true}], "snippet_links": [{"key": "program-aptamer", "type": "definition", "offset": [10, 25]}, {"key": "program-target", "type": "definition", "offset": [37, 51]}, {"key": "conduct-of-the-research-program", "type": "clause", "offset": [84, 115]}, {"key": "development-program", "type": "definition", "offset": [119, 138]}, {"key": "collaboration-aptamer", "type": "definition", "offset": [286, 307]}], "snippet": "means any Program Aptamer that [***] Program Target that is first identified in the conduct of the Research Program or Development Program, or any Aptamer [***] first identified in the conduct of the Research Program or Development Program that [***] Program Target; provided, that, no Collaboration Aptamer shall, after [***], be nominated or designated as a Lead Compound.", "size": 4, "hash": "05b63620bcf62a55a30c90bef89fcb65", "id": 10}], "next_curs": "CloSVGoVc35sYXdpbnNpZGVyY29udHJhY3RzcjYLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIWbGVhZC1jb21wb3VuZCMwMDAwMDAwYQyiAQJlbhgAIAA=", "definition": {"title": "Lead Compound", "snippet": "means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid, a quantity of soluble lead compound exceeding, when calculated as lead monoxide, five per cent of the \u201cdry weight\u201d of the portion taken for analysis. In the case of paints and similar products and other mixtures containing oil or fat the \u201cdry weight\u201d means the dry weight of the material remaining after the substance has been thoroughly mixed and treated with suitable solvents to remove oil, fats, varnish or other media.", "size": 354, "id": "lead-compound", "examples": ["Bambusa will not terminate, amend, waive, or otherwise modify (or consent to any of the foregoing) its rights under the Bambusa [***] Agreement in a manner that materially diminishes the rights or licenses granted to Bambusa to receive the Transferred Cell Line as contemplated by Section 2.10.3 (Transfer of Materials) or to use the Transferred Cell Line to produce the <strong>Lead Compound</strong> for the purposes contemplated by this Agreement.", "During the [***]-day period following the Program Transfer Date, Biotheus will provide to Bambusa copies of all Know-How included within the Licensed Know-How as of the Program Transfer Date (in its original form), including copies of Schedule 1.58 (<strong>Lead Compound</strong>) and Schedule 1.6 (Back-up Compounds) setting forth the amino acid sequence of the <strong>Lead Compound</strong> and each Back-up Compound, respectively."], "related": [["collaboration-compound", "Collaboration Compound", "Collaboration Compound"], ["licensed-compound", "Licensed Compound", "Licensed Compound"], ["development-candidate", "Development Candidate", "Development Candidate"], ["product-candidate", "Product Candidate", "Product Candidate"], ["licensed-compounds", "Licensed Compounds", "Licensed Compounds"]], "related_snippets": [], "updated": "2026-10-13T06:09:29+00:00"}, "json": true, "cursor": ""}}